Addition of Rifampin to Antimicrobial Therapy Does Not Improve Success Rate in Staphylococcal PJI .
This report has been verified
by one or more authors of the
original publication.
Rifampin combination therapy in staphylococcal prosthetic joint infections: a randomized controlled trial.
J Orthop Surg Res. 2020; 15: 365.Sixty-five patients with staphylococcal peri-prosthetic joint infections of the hip or knee were randomized to receive debridement and wound excision plus 6 weeks of antimicrobial therapy (intravenous cloxacillin or vancomycin), with or without the addition of oral rifampin. The outcome of interest was treatment success at 2 years follow up, defined as a lack of clinical signs of peri-prosthetic joint infection, C-reactive protein levels < 10mg/mL, erythrocyte sedimentation rate as prior to index operation, and no radiological signs of loosening. No significant difference in treatment success rate was observed between the rifampin and control groups at 2 years post-treatment. Moreover in the sub-group analysis by bacteria type (Staphylococcus aureus; Coagulase-negative staphylococci), no significant differences in treatment success rate were observed between the two groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
